Lilly (Eli)LLYEarnings & Financial Report
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
Revenue
$11.4B
Gross Profit
$9.3B
Operating Profit
$1.6B
Net Profit
$970.3M
Gross Margin
81.0%
Operating Margin
13.9%
Net Margin
8.5%
YoY Growth
20.4%
EPS
$1.07
Lilly (Eli) Q3 FY2024 Financial Summary
Lilly (Eli) reported revenue of $11.4B (up 20.4% YoY) for Q3 FY2024, with a net profit of $970.3M (up 1790.4% YoY) (8.5% margin). Cost of goods sold was $2.2B, operating expenses totaled $7.7B.
Key Financial Metrics
| Total Revenue | $11.4B |
|---|---|
| Net Profit | $970.3M |
| Gross Margin | 81.0% |
| Operating Margin | 13.9% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Lilly (Eli) Q3 FY2024 revenue of $11.4B breaks down across 8 segments, led by Products at $10.6B (92.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $10.6B | 92.4% |
| Jardiance | $335.9M | 2.9% |
| Humulin | $149.9M | 1.3% |
| Erbitux | $133.2M | 1.2% |
| Other Product Total | $107.0M | 0.9% |
| Basaglar | $85.5M | 0.7% |
| Other Cardiometabolic Health | $35.8M | 0.3% |
| Baqsimi | $8.2M | 0.1% |
Lilly (Eli) Revenue by Segment — Quarterly Trend
Lilly (Eli) revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Jardiance) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Jardiance | $465.8M | $424.2M | $382.2M | $309.8M |
| Other Product Total | $77.0M | $44.8M | $82.7M | $99.5M |
Lilly (Eli) Annual Revenue by Year
Lilly (Eli) annual revenue history includes year-by-year totals (for example, 2025 revenue was $65.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $65.2B |
| 2024 | $45.0B |
| 2023 | $34.1B |
| 2022 | $28.5B |
Lilly (Eli) Quarterly Revenue & Net Profit History
Lilly (Eli) results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $19.3B | +42.6% | $6.6B | 34.4% |
| Q3 FY2025 | $17.6B | +53.9% | $5.6B | 31.7% |
| Q2 FY2025 | $15.6B | +37.6% | $5.7B | 36.4% |
| Q1 FY2025 | $12.7B | +45.2% | $2.8B | 21.7% |
| Q4 FY2024 | $13.5B | +44.7% | $4.4B | 32.6% |
| Q3 FY2024 | $11.4B | +20.4% | $970.3M | 8.5% |
| Q2 FY2024 | $11.3B | +36.0% | $3.0B | 26.3% |
| Q1 FY2024 | $8.8B | +26.0% | $2.2B | 25.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.77B | $11.30B | $11.44B | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B |
| YoY Growth | 26.0% | 36.0% | 20.4% | 44.7% | 45.2% | 37.6% | 53.9% | 42.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $63.94B | $71.87B | $75.61B | $78.71B | $89.39B | $100.92B | $114.94B | $112.48B |
| Liabilities | $51.13B | $58.31B | $61.37B | $64.52B | $73.62B | $82.65B | $91.14B | $85.94B |
| Equity | $12.81B | $13.56B | $14.24B | $14.19B | $15.76B | $18.27B | $23.79B | $26.54B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.17B | $1.47B | $3.71B | $2.47B | $1.67B | $3.09B | $8.84B | $3.22B |